Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $0.28 in the prior trading day, Processa Pharmaceuticals Inc (NASDAQ: PCSA) closed at $0.27, down -1.77%. In other words, the price has decreased by -$1.77 from its previous closing price. On the day, 1.05 million shares were traded. PCSA stock price reached its highest trading level at $0.2818 during the session, while it also had its lowest trading level at $0.2593.
Ratios:
Our goal is to gain a better understanding of PCSA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.76 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on April 25, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 27 ’25 when Yorke Justin W bought 12,400 shares for $0.80 per share. The transaction valued at 9,889 led to the insider holds 12,400 shares of the business.
Ng George K bought 87,200 shares of PCSA for $69,542 on Jan 27 ’25. The Chief Executive Officer now owns 87,200 shares after completing the transaction at $0.80 per share. On Jan 27 ’25, another insider, Young David, who serves as the Pres. Research & Development of the company, bought 124,500 shares for $0.80 each. As a result, the insider paid 99,289 and bolstered with 205,405 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCSA now has a Market Capitalization of 15407230 and an Enterprise Value of 9098809.
Stock Price History:
The Beta on a monthly basis for PCSA is 1.07, which has changed by -0.75495493 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, PCSA has reached a high of $1.45, while it has fallen to a 52-week low of $0.15. The 50-Day Moving Average of the stock is -12.99%, while the 200-Day Moving Average is calculated to be -3.32%.
Shares Statistics:
The stock has traded on average 9.61M shares per day over the past 3-months and 800070 shares per day over the last 10 days, according to various share statistics. A total of 52.86M shares are outstanding, with a floating share count of 49.24M. Insiders hold about 13.07% of the company’s shares, while institutions hold 3.14% stake in the company. Shares short for PCSA as of 1764288000 were 5434144 with a Short Ratio of 0.57, compared to 1761868800 on 9049525. Therefore, it implies a Short% of Shares Outstanding of 5434144 and a Short% of Float of 9.6999995.
Earnings Estimates
. The current market rating for Processa Pharmaceuticals Inc (PCSA) reflects the collective analysis of 1.0 analysts closely monitoring its performance.
Analysts are recommending an EPS of between -$0.43 and -$0.43 for the fiscal current year, implying an average EPS of -$0.43. EPS for the following year is -$0.15, with 1.0 analysts recommending between -$0.15 and -$0.15.
